{
  "DOI": "10.1007/s10689-019-00122-y",
  "ISSN": [
    "1389-9600",
    "1573-7292"
  ],
  "URL": "http://dx.doi.org/10.1007/s10689-019-00122-y",
  "alternative-id": [
    "122"
  ],
  "assertion": [
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "First Online",
      "name": "first_online",
      "order": 1,
      "value": "28 January 2019"
    },
    {
      "group": {
        "label": "Compliance with ethical standards",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 1
    },
    {
      "group": {
        "label": "Conflict of interest",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 2,
      "value": "SW, MP, DS, JL, OY, and NH declare that they have no conflict of interest. CG has sat on Advisory Boards for AstraZeneca, Clovis and Tesaro, has received lecture fees and research funding from AstraZeneca and Tesaro."
    },
    {
      "group": {
        "label": "Ethical approval",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 3,
      "value": "The study was approved by the University of Edinburgh Research Ethics Committee, The Quality Improvement Team and the Caldicott Guardian at the Western General Hospital, Edinburgh. All interviewees gave their consent for publication of their interview data."
    }
  ],
  "author": [
    {
      "ORCID": "http://orcid.org/0000-0002-7647-8524",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Hallowell",
      "given": "Nina",
      "sequence": "first"
    },
    {
      "affiliation": [],
      "family": "Wright",
      "given": "S.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Stirling",
      "given": "D.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Gourley",
      "given": "C.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Young",
      "given": "O.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Porteous",
      "given": "M.",
      "sequence": "additional"
    }
  ],
  "container-title": [
    "Familial Cancer"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": [
      "link.springer.com"
    ]
  },
  "created": {
    "date-parts": [
      [
        2019,
        1,
        28
      ]
    ],
    "date-time": "2019-01-28T05:29:12Z",
    "timestamp": 1548653352000
  },
  "deposited": {
    "date-parts": [
      [
        2020,
        1,
        28
      ]
    ],
    "date-time": "2020-01-28T00:16:38Z",
    "timestamp": 1580170598000
  },
  "funder": [
    {
      "DOI": "10.13039/100009794",
      "award": [
        "[2016MayPR700]"
      ],
      "doi-asserted-by": "publisher",
      "name": "Breast Cancer Now"
    }
  ],
  "indexed": {
    "date-parts": [
      [
        2024,
        4,
        19
      ]
    ],
    "date-time": "2024-04-19T02:03:57Z",
    "timestamp": 1713492237555
  },
  "is-referenced-by-count": 41,
  "issn-type": [
    {
      "type": "print",
      "value": "1389-9600"
    },
    {
      "type": "electronic",
      "value": "1573-7292"
    }
  ],
  "issue": "3",
  "issued": {
    "date-parts": [
      [
        2019,
        1,
        28
      ]
    ]
  },
  "journal-issue": {
    "issue": "3",
    "published-print": {
      "date-parts": [
        [
          2019,
          7
        ]
      ]
    }
  },
  "language": "en",
  "license": [
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "tdm",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2019,
            1,
            28
          ]
        ],
        "date-time": "2019-01-28T00:00:00Z",
        "timestamp": 1548633600000
      }
    }
  ],
  "link": [
    {
      "URL": "http://link.springer.com/article/10.1007/s10689-019-00122-y/fulltext.html",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "http://link.springer.com/content/pdf/10.1007/s10689-019-00122-y.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "http://link.springer.com/content/pdf/10.1007/s10689-019-00122-y.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "page": "293-301",
  "prefix": "10.1007",
  "published": {
    "date-parts": [
      [
        2019,
        1,
        28
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2019,
        1,
        28
      ]
    ]
  },
  "published-print": {
    "date-parts": [
      [
        2019,
        7
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "DOI": "10.1002/(SICI)1097-0142(19960601)77:11\u003c2318::AID-CNCR21\u003e3.0.CO;2-Z",
      "author": "EB Claus",
      "doi-asserted-by": "publisher",
      "first-page": "2318",
      "journal-title": "Cancer",
      "key": "122_CR1",
      "unstructured": "Claus EB, Schildkraut JM, Thompson WD et al (1996) The genetic attributable risk of breast and ovarian cancer. Cancer 77:2318–2324",
      "volume": "77",
      "year": "1996"
    },
    {
      "DOI": "10.1016/j.ygyno.2011.01.020",
      "author": "S Zhang",
      "doi-asserted-by": "publisher",
      "first-page": "353",
      "journal-title": "Gynecol Oncol",
      "key": "122_CR2",
      "unstructured": "Zhang S, Royer R, Li S et al (2011) Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol 121:353–357",
      "volume": "121",
      "year": "2011"
    },
    {
      "DOI": "10.1001/jama.2017.7112",
      "author": "KB Kuchenbaecker",
      "doi-asserted-by": "publisher",
      "first-page": "2402",
      "journal-title": "JAMA",
      "key": "122_CR3",
      "unstructured": "Kuchenbaecker KB, Hopper JL, Barnes DR et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317:2402–2416",
      "volume": "317",
      "year": "2017"
    },
    {
      "DOI": "10.1016/S0140-6736(02)08434-9",
      "author": "BG Haffty",
      "doi-asserted-by": "publisher",
      "first-page": "1471",
      "journal-title": "Lancet",
      "key": "122_CR4",
      "unstructured": "Haffty BG, Harrold E, Khan AJ et al (2002) Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 359:1471–1477",
      "volume": "359",
      "year": "2002"
    },
    {
      "key": "122_CR5",
      "unstructured": "National Institute for Health and Clinical Excellence (2013) Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. NICE guideline [CG164]. National Institute for Health and Clinical Excellence"
    },
    {
      "DOI": "10.1038/nrclinonc.2016.191",
      "author": "A George",
      "doi-asserted-by": "publisher",
      "first-page": "284",
      "journal-title": "Nat Rev Clin Oncol",
      "key": "122_CR6",
      "unstructured": "George A, Kaye S, Banerjee S (2017) Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. Nat Rev Clin Oncol 14:284–296",
      "volume": "14",
      "year": "2017"
    },
    {
      "DOI": "10.1001/archsurg.138.12.1323",
      "doi-asserted-by": "publisher",
      "key": "122_CR7",
      "unstructured": "Weitzel JN, McCaffrey SM, Nedelcu R et al. Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. Arch Surg. \n                    https://doi.org/10.1001/archsurg.138.12.1323"
    },
    {
      "DOI": "10.1200/JCO.2014.57.0085",
      "author": "ML Telli",
      "doi-asserted-by": "publisher",
      "first-page": "1895",
      "journal-title": "J Clin Oncol",
      "key": "122_CR8",
      "unstructured": "Telli ML, Jensen KC, Vinayak S, et a (2015) Phase II study of gemcitabine, carboplatin, and imiparib as neoadjuvant therapy for triple-negative and BRCA1/2 mutation-associated breast cancer with assessment of a tumor-based measure of genomic instability: PrECOG 0105. J Clin Oncol 33:1895–1901",
      "volume": "33",
      "year": "2015"
    },
    {
      "DOI": "10.1038/s41591-018-0009-7",
      "doi-asserted-by": "publisher",
      "key": "122_CR9",
      "unstructured": "Tutt A, Tovey H, Cheang MCU et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med. \n                    https://doi.org/10.1038/s41591-018-0009-7"
    },
    {
      "DOI": "10.18632/oncotarget.17005",
      "author": "S Rafii",
      "doi-asserted-by": "publisher",
      "journal-title": "Oncotarget",
      "key": "122_CR10",
      "unstructured": "Rafii S, Gourley C, Kumar R et al (2017) Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer. Oncotarget. \n                    https://doi.org/10.18632/oncotarget.17005",
      "year": "2017"
    },
    {
      "author": "SC Davies",
      "key": "122_CR11",
      "unstructured": "Davies SC (2017) Annual report of the Chief Medical Officer 2016, generation genome. Department of Health, London",
      "volume-title": "Annual report of the Chief Medical Officer 2016, generation genome",
      "year": "2017"
    },
    {
      "key": "122_CR12",
      "unstructured": "Independent Cancer Taskforce (2015) Achieving world-class cancer outcomes a strategy for England 2015–2020"
    },
    {
      "DOI": "10.1186/s13073-015-0128-4",
      "doi-asserted-by": "publisher",
      "key": "122_CR13",
      "unstructured": "Slade I, Riddell D, Turnbull C et al. Development of cancer genetic services in the UK: a national consultation. Genome Med. \n                    https://doi.org/10.1186/s13073-015-0128-4"
    },
    {
      "DOI": "10.1186/1472-6963-10-125",
      "doi-asserted-by": "publisher",
      "key": "122_CR14",
      "unstructured": "Bennett CL, Burke SE, Burton H et al. A toolkit for incorporating genetics into mainstream medical services: learning from service development pilots in England. BMC Health Serv Res. \n                    https://doi.org/10.1186/1472-6963-10-125"
    },
    {
      "DOI": "10.12968/bjon.2016.25.12.690",
      "doi-asserted-by": "publisher",
      "key": "122_CR15",
      "unstructured": "Percival N, George A, Gyertson J et al. The integration of BRCA testing into oncology clinics. Br J Nurs. \n                    https://doi.org/10.12968/bjon.2016.25.12.690"
    },
    {
      "DOI": "10.1016/j.ygyno.2017.01.030",
      "author": "M Kentwell",
      "doi-asserted-by": "publisher",
      "first-page": "130",
      "journal-title": "Gynecol Oncol",
      "key": "122_CR16",
      "unstructured": "Kentwell M, Dow E, Antill Y et al (2017) Mainstreaming cancer genetics: a model integrating germline BRCA testing into routine ovarian cancer clinics. Gynecol Oncol 145:130–136",
      "volume": "145",
      "year": "2017"
    },
    {
      "DOI": "10.1136/jmedgenet-2017-105140",
      "doi-asserted-by": "publisher",
      "key": "122_CR17",
      "unstructured": "Rahman B, Lanceley A, Kristeleit RS et al. Mainstreamed genetic testing for women with ovarian cancer: first-year experience. J Med Genet. \n                    https://doi.org/10.1136/jmedgenet-2017-105140"
    },
    {
      "DOI": "10.1200/JCO.2017.76.2369",
      "doi-asserted-by": "publisher",
      "key": "122_CR18",
      "unstructured": "Katz SJ, Ward KC, Hamilton AS et al. Gaps in receipt of clinically indicated genetic counselling after diagnosis of breast cancer. J Clin Oncol. \n                    https://doi.org/10.1200/JCO.2017.76.2369"
    },
    {
      "DOI": "10.1001/jama.2015.8088",
      "doi-asserted-by": "publisher",
      "key": "122_CR19",
      "unstructured": "Katz SJ, Kurian AW, Morrow M. Treatment decision making and genetic testing for breast cancer: mainstreaming mutations. JAMA. \n                    https://doi.org/10.1001/jama.2015.8088"
    },
    {
      "DOI": "10.2217/pme.13.45",
      "doi-asserted-by": "publisher",
      "key": "122_CR20",
      "unstructured": "Burcher S, Meiser B, Mitchell G Oncology health professionals’ attitudes toward treatment-focused genetic testing for women newly diagnosed with breast cancer. Personal Med. \n                    https://doi.org/10.2217/pme.13.45"
    },
    {
      "DOI": "10.1007/s10689-014-9770-z",
      "doi-asserted-by": "publisher",
      "key": "122_CR21",
      "unstructured": "Douma KFL, Meiser B, Kirk J et al. Health professionals’ evaluation of delivering treatment-focused genetic testing to women newly diagnosed with breast cancer. Fam Cancer. \n                    https://doi.org/10.1007/s10689-014-9770-z"
    },
    {
      "DOI": "10.1200/JCO.2016.71.6480",
      "doi-asserted-by": "publisher",
      "key": "122_CR22",
      "unstructured": "Kurian AW, Li Y, Hamilton AS et al. Gaps in incorporating germline genetic testing into treatment decision-making for early-stage breast cancer. J Clin Oncol. \n                    https://doi.org/10.1200/JCO.2016.71.6480"
    },
    {
      "DOI": "10.1186/s12885-015-1934-1",
      "doi-asserted-by": "publisher",
      "key": "122_CR23",
      "unstructured": "Eccles BK, Copson E, Maishman T et al. Understanding of BRCA VUS genetic results by breast cancer specialists. BMC Cancer. \n                    https://doi.org/10.1186/s12885-015-1934-1"
    },
    {
      "author": "JA Maxwell",
      "key": "122_CR24",
      "unstructured": "Maxwell JA (2012) Qualitative research design: an interactive approach, vol 41. Sage Publications, London",
      "volume-title": "Qualitative research design: an interactive approach",
      "year": "2012"
    },
    {
      "DOI": "10.1038/gim.2014.101",
      "author": "NA Mikat-Stevens",
      "doi-asserted-by": "publisher",
      "first-page": "169",
      "journal-title": "Genet Med",
      "key": "122_CR25",
      "unstructured": "Mikat-Stevens NA, Larson IA, Tarini BA (2015) Primary-care providers’ perceived barriers to integration of genetics services: a systematic review of the literature. Genet Med 17:169–176",
      "volume": "17",
      "year": "2015"
    },
    {
      "DOI": "10.1258/jhsrp.2009.008158",
      "doi-asserted-by": "publisher",
      "key": "122_CR26",
      "unstructured": "Martin G, Currie G, Finn RJ, Health Services Research Policy. Bringing genetics into primary care: findings from a national evaluation of pilots in England. J Health Serv Res Policy. \n                    https://doi.org/10.1258/jhsrp.2009.008158"
    },
    {
      "DOI": "10.1016/j.socscimed.2003.10.025",
      "author": "R Robins",
      "doi-asserted-by": "publisher",
      "first-page": "223",
      "journal-title": "Soc Sci Med",
      "key": "122_CR27",
      "unstructured": "Robins R, Metcalfe S (2004) Integrating genetics as practices of primary care. Soc Sci Med 59:223–233",
      "volume": "59",
      "year": "2004"
    },
    {
      "DOI": "10.1038/gim.2013.75",
      "doi-asserted-by": "publisher",
      "key": "122_CR28",
      "unstructured": "Scheuner MT, Hamilton AB, Peredo J et al. A cancer genetics toolkit improves access to genetic services through documentation and use of the family history by primary-care clinicians. Genet Med. \n                    https://doi.org/10.1038/gim.2013.75"
    },
    {
      "DOI": "10.1186/s12920-017-0273-2",
      "doi-asserted-by": "publisher",
      "key": "122_CR29",
      "unstructured": "Sperber NR, Carpenter JR, Cavallari LH et al. Challenges and strategies for implementing genomic services in diverse settings: experiences from the Implementing GeNomics In pracTicE (IGNITE) network. BMC Med Genomics. \n                    https://doi.org/10.1186/s12920-017-0273-2"
    }
  ],
  "reference-count": 29,
  "references-count": 29,
  "resource": {
    "primary": {
      "URL": "http://link.springer.com/10.1007/s10689-019-00122-y"
    }
  },
  "score": 0,
  "short-container-title": [
    "Familial Cancer"
  ],
  "source": "Crossref",
  "title": [
    "Moving into the mainstream: healthcare professionals’ views of implementing treatment focussed genetic testing in breast cancer care"
  ],
  "type": "journal-article",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
  "volume": "18"
}